Brands
Johnnie Walker Luxe Blended Water debuts ‘The Walkers List’
MUMBAI: For over 25 years, Keep Walking has been a rallying cry for bold progress and purposeful action. In its latest expression of this enduring philosophy, Johnnie Walker Luxe Blended Water presents The Walkers List — an avant garde cultural platform bringing together changemakers, creators and innovators all toward creating a movement that embraces the spirit of progress.
The Walkers List brings together a collective of celebrated individuals who challenge norms, reimagine possibilities, and leave a lasting imprint on their communities and the culture at large. At its heart, The Walkers List seeks to inspire purposeful action through collaboration, providing a stage for those who represent the virtue of never standing still.
The platform, in its inaugural edition, is supporting a collective of creative disruptors and collaborators that redefine boundaries and progress in the fields of art, dance, music, and fashion. So, get ready to experience:
. The Walkers Jersey by Virat Kohli x Saina Nehwal – A transformative collaboration that transcends sports to champion equality and progress. Co-created by two of India’s most celebrated sporting icons, this exclusive jersey embodies a powerful commitment to elevating women’s sports and creating equal opportunities. Designed not just for athletes but for every advocate who believes in gender equality in sports, The Walkers Jersey invites supporters to wear their values and walk alongside the change they wish to see.
. Paizār-e-Pashm by Babar Afzal × Aprajita Toor– A bold reimagining of artisanal heritage, where traditional cashmere pashmina craftsmanship meets culturally inspired yet modern footwear designs, to create a timeless impact. Proceeds from the sale of the footwear will go towards the upliftment of the sustainable cashmere pashmina shepherding and artisanal community by Pashmina Goat Project and an NGO supporting handicraft artists in keeping alive traditional arts of India.
. Dhwani by Shilo Shiv Suleman × Colleena Shakti – An immersive art installation that brings together handcrafted metalwork and responsive movement to create a living expression of “keep walking”. This installation was successfully showcased on 27th July, 2025, at Snowball Studios, Worli. This collaboration celebrates community and craft, featuring master Lohar artisans from Jaipur and local Odissi dancers who worked closely to blend traditional Indian metalworking and dance techniques with contemporary vision. The 250-kilogram golden spiral installation transcends static art through movement, light, and human connection, while creating sustainable opportunities for craftsmen and preserving cultural heritage.
. The Planet Song by Ricky Kej × Rashmeet Kaur – A powerful sonic exploration advocating for sustainability and social change through genre-defying track by a Grammy award winning artist and an innovator on traditional folk music forms from India.
With these bold new creations, The Walkers List ignites a powerful cultural shift — inviting audiences to discover how purpose-driven collaborations and fearless creativity are shaping the future, one boundary-breaking idea at a time.
“Johnnie Walker Blended Luxe Water believes progress is never a solo journey. The Walkers List was created to champion individuals who are challenging conventions and shaping the future through creativity and community impact,” said Diageo India CMO Ruchira Jaitly (USL). “With this initiative, we bring the Keep Walking narrative to life — not just through words, but through impactful, positive action.”
Brands
Sun Pharma to acquire Organon in $11.75 billion deal at $14 per share
Acquisition to create $12.4 billion pharma giant with global scale and biosimilars push
MUMBAI: Sun Pharmaceutical Industries Limited has signed a definitive agreement to acquire Organon & Co. in an all-cash deal valued at $11.75 billion, marking one of the largest cross-border pharma acquisitions by an Indian firm.
Under the terms of the agreement, Organon shareholders will receive $14.00 per share in cash, with Sun Pharma set to acquire 100 per cent of the company’s outstanding shares. The transaction, approved by the boards of both companies, is expected to close in early 2027, subject to regulatory approvals and shareholder consent.
The deal significantly expands Sun Pharma’s global footprint and strengthens its position across women’s health, biosimilars, and branded generics. The combined entity is projected to generate revenues of around $12.4 billion, placing it among the top 25 pharmaceutical companies globally.
Organon, which was spun off from Merck in 2021, brings a portfolio of over 70 products spanning women’s health and general medicines, with operations across more than 140 countries. Its established presence in key markets such as the US, Europe, and China complements Sun Pharma’s existing strengths and growth ambitions.
Sun Pharmaceutical Industries Limited executive chairman Dilip Shanghvi said, “This transaction represents a significant opportunity for Sun Pharma to build on its vision of reaching people and touching lives. Organon’s portfolio, capabilities and global reach are highly complementary to our own.”
Sun Pharmaceutical Industries Limited managing director Kirti Ganorkar added, “This transaction is a logical next step in strengthening Sun Pharma’s global business. Together, we will become a partner of choice for acquiring and launching new products.”
From Organon’s side, Organon & Co. executive chair Carrie Cox noted, “This all-cash transaction offers compelling and immediate value to Organon stockholders, while positioning the business for continued growth under Sun Pharma.”
Strategically, the acquisition gives Sun Pharma entry into the global biosimilars space as a top 10 player and strengthens its innovative medicines portfolio, which is expected to contribute around 27 per cent of combined revenues. The deal is also expected to nearly double EBITDA and cash flow, supporting long-term deleveraging and investment capacity.
Sun Pharma plans to fund the acquisition through a mix of internal accruals and committed financing from global banks, while maintaining focus on disciplined integration and operational continuity post-merger.
If completed as planned, the deal signals a clear shift in India’s pharmaceutical ambitions, from scale at home to leadership on the global stage, with Sun Pharma positioning itself as a more diversified and innovation-led healthcare powerhouse.
